Search

Although fused deposition modeling (FDM) has made it possible to create reproducible three-dimensional poly(lactic acid) (PLA) scaffolds, their efficacy for tissue engineering applications is limited by their lack of osteoinductive properties and antibacterial functions. Building on the success of the FDM constructs capable of supporting bone regeneration, we report here on the development of PLA scaffolds infused with sodium alginate cross-linked with both calcium and zinc divalent cations. Zn 2+ cations were used to confer antibacterial and osteoinductive properties to enhance the performance of nontoxic PLA-alginate. Both the PLA and alginate polymers have been approved by the US Food and Drug Administration. In vivo bone regeneration capacity was demonstrated on a rabbit model by tomography and histological analysis. The scaffolds exhibited antibacterial activity against Gram-positive methicillin-resistant Staphylococcus epidermidis and Gram-negative Pseudomonas aeruginosa , while the control scaffolds could not resist the two microbial species tested. The scaffolds' physical properties were evaluated by field emission scanning electron microscopy with energy-disperse X-ray spectroscopy, Fourier transform infrared spectroscopy, water absorption, porosity measurements, and compression tests in dry and swollen states at body temperature. Their superior compressive properties, water uptake, and osteoinductive and antibacterial activities thus make them promising candidates for bone tissue regeneration.

The Federal Occupational Safety and Health Administration (OSHA) maintains standards (Standards) that define structural requirements for elements that support suspended scaffolds and fall arrest lanyards when this equipment is used to access facades and other elevated portions of buildings. The Standards are available online at www.osha.gov. Ensuring that applicable requirements are met is the responsibility of a qualified person—typically a professional engineer. However, navigating and applying the OSHA structural provisions can be difficult primarily because relevant requirements are not located in a single document, structural requirements vary for different uses, and structural requirements are not always written in a manner consistent with typical structural engineering practice. The rational application of key OSHA structural provisions when designing suspended scaffold support elements and lifeline anchorages is the subject of a companion paper, “Designing Suspended Scaffold Structural Support Elements and Lifeline Anchorages in Conformance with Federal OSHA Requirements,” which is included in this publication. The objective of this paper is to promote the rational application of sound engineering principles when certifying the adequacy of existing elements and their compliance with OSHA Standards. Unfortunately, certain trends and recent developments in the facade access equipment industry have made proper certification more difficult than it needs to be; irrational approaches and conclusions are, at times, actually encouraged by industry groups. [ABSTRACT FROM AUTHOR]

Spinal cord injury (SCI) is a disease of the central nervous system (CNS) that has not yet been treated successfully. In the United States, almost 450,000 people suffer from SCI. Despite the development of many clinical treatments, therapeutics are still at an early stage for a successful bridging of damaged nerve spaces and complete recovery of nerve functions. Biomimetic 3D scaffolds have been an effective option in repairing the damaged nervous system. 3D scaffolds allow improved host tissue engraftment and new tissue development by supplying physical support to ease cell function. Recently, 3D bioprinting techniques that may easily regulate the dimension and shape of the 3D tissue scaffold and are capable of producing scaffolds with cells have attracted attention. Production of biologically more complex microstructures can be achieved by using 3D bioprinting technology. Particularly in vitro modeling of CNS tissues for in vivo transplantation is critical in the treatment of SCI. Considering the potential impact of 3D bioprinting technology on neural studies, this review focus on 3D bioprinting methods, bio-inks, and cells widely used in neural tissue engineering and the latest technological applications of bioprinting of nerve tissues for the repair of SCI are discussed. • 3D bioprinting applications for spinal cord injury repair • Different 3D bioprinting technologies on neural tissue engineering • 3D bioprinted scaffold for neural tissue engineering [ABSTRACT FROM AUTHOR]

The aim of this study was to develop and evaluate an optimized 3D bioprinting technology in order to fabricate novel scaffolds for the application of endothelial cell repair. Various biocompatible and biodegradable macroporous scaffolds (D = 10 mm) with interconnected pores (D = ~500 µm) were fabricated using a commercially available 3D bioprinter (r3bEL mini, SE3D, USA). The resolution of the printing layers was set at ~100 µm for all scaffolds. Various compositions of polylactic acid (PLA), polyethylene glycol (PEG) and pluronic F127 (F127) formulations were prepared and optimized to develop semi-solid viscous bioinks. Either dimethyloxalylglycine (DMOG) or erythroprotein (EPO) was used as a model drug and loaded in the viscous biocompatible ink formulations with a final concentration of 30% (w/w). The surface analysis of the bioinks via a spectroscopic analysis revealed a homogenous distribution of the forming materials throughout the surface, whereas SEM imaging of the scaffolds showed a smooth surface with homogenous macro-porous texture and precise pore size. The rheological and mechanical analyses showed optimum rheological and mechanical properties of each scaffold. As the drug, DMOG, is a HIF-1 inducer, its release from the scaffolds into PBS solution was measured indirectly using a bioassay for HIF-1α. This showed that the release of DMOG was sustained over 48 h. The release of DMOG was enough to cause a significant increase in HIF-1α levels in the bioassay, and when incubated with rat aortic endothelial cells (RAECs) for 2 h resulted in transcriptional activation of a HIF-1α target gene (VEGF). The optimum time for the increased expression of VEGF gene was approximately 30 min and was a 3-4-fold increase above baseline. This study provides a proof of concept, that a novel bioprinting platform can be exploited to develop biodegradable composite scaffolds for potential clinical applications in endothelial cell repair in cardiovascular disease (CVD), or in other conditions in which endothelial damage occurs. [ABSTRACT FROM AUTHOR]